Nano-Micro Letters

Manganese-Zeolitic Imidazolate Frameworks-90 with High Blood Circulation Stability for Magnetic Resonance Imaging-Guided Tumor Therapy

Zhenqi Jiang1, 3, †, Bo Yuan1, †, Nianxiang Qiu1, Yinjie Wang1, 3, Li Sun1, 3, Zhenni Wei1, Yanyin Li1, 3, Jianjun Zheng2, Yinhua Jin2, Yong Li1, Shiyu Du1, Juan Li1, *, Aiguo Wu1, *

Abstract | Support Info
icon-htmlFull Text Html
icon-pdf-smPDF w/ Links
icon-citExport Citation
+Show more

Nano-Micro Lett. (2019) 11: 61

First Online: 23 July 2019 (Article)


*Corresponding author. E-mail: aiguo@nimte.ac.cn (Aiguo Wu); lij@nimte.ac.cn (Juan Li)





Zeolitic imidazolate frameworks (ZIFs) as smart drug delivery systems with microenvironment-triggered release have attracted much attention for tumor therapy. However, the exploration of ZIFs in biomedicine still encounters many issues, such as inconvenient surface modification, fast drug release during blood circulation, undesired damage to major organs, and severe in vivo toxicity. To address the above issues, we developed an Mn-ZIF-90 nanosystem functionalized with an originally designed active-targeting and pH-responsive Y1 receptor ligand [Asn28, Pro30, Trp32]-NPY (25-36) for imaging-guided tumor therapy. After Y1 receptor ligand modification, the Mn-ZIF-90 nanosystem exhibited high drug loading, better blood circulation stability, and dual breast cancer cell membrane and mitochondria targetability, further favoring specific microenvironment-triggered tumor therapy. Meanwhile, this nanosystem showed promising T1-weighted magnetic resonance imaging contrast in vivo in the tumor sites. Especially, this nanosystem with fast clean-up had almost no obvious toxicity and no damage occurred to the major organs in mice. Therefore, this nanosystem shows potential for use in imaging-guided tumor therapy.



Zeolitic imidazolate frameworks-90; Drug delivery system; Magnetic resonance imaging; pH-responsive release; Y1 receptor ligand

 View: Full Text HTML | PDF w/ Links